BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36402456)

  • 1. Characterization and Function of Cryopreserved Bone Marrow from Deceased Organ Donors: A Potential Viable Alternative Graft Source.
    Johnstone BH; Woods JR; Goebel WS; Gu D; Lin CH; Miller HM; Musall KG; Sherry AM; Bailey BJ; Sims E; Sinn AL; Pollok KE; Spellman S; Auletta JJ; Woods EJ
    Transplant Cell Ther; 2023 Feb; 29(2):95.e1-95.e10. PubMed ID: 36402456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Large-Scale Bank of Organ Donor Bone Marrow and Matched Mesenchymal Stem Cells for Promoting Immunomodulation and Transplant Tolerance.
    Johnstone BH; Messner F; Brandacher G; Woods EJ
    Front Immunol; 2021; 12():622604. PubMed ID: 33732244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryopreservation of Allogeneic Hematopoietic Cell Products During COVID-19 Pandemic: Graft Characterization and Engraftment Outcomes.
    Keyzner A; Azzi J; Jakubowski R; Sinitsyn Y; Tindle S; Shpontak S; Kwon D; Isola L; Iancu-Rubin C
    Transplant Proc; 2023 Oct; 55(8):1799-1809. PubMed ID: 37210273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
    Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
    Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.
    Hsu JW; Farhadfar N; Murthy H; Logan BR; Bo-Subait S; Frey N; Goldstein SC; Horowitz MM; Lazarus H; Schwanke JD; Shah NN; Spellman SR; Switzer GE; Devine SM; Shaw BE; Wingard JR
    Transplant Cell Ther; 2021 Jun; 27(6):507-516. PubMed ID: 33865804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation.
    Rybka WB; Fontes PA; Rao AS; Winkelstein A; Ricordi C; Ball ED; Starzl TE
    Transplantation; 1995 Mar; 59(6):871-4. PubMed ID: 7701582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ischemia considerations for the development of an organ and tissue donor derived bone marrow bank.
    Woods EJ; Sherry AM; Woods JR; Hardin JW; LaFontaine M; Brandacher G; Johnstone BH
    J Transl Med; 2020 Aug; 18(1):300. PubMed ID: 32758261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
    Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
    Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentaisomaltose, an Alternative to DMSO. Engraftment of Cryopreserved Human CD34
    Svalgaard JD; Talkhoncheh MS; Haastrup EK; Munthe-Fog L; Clausen C; Hansen MB; Andersen P; Gørløv JS; Larsson J; Fischer-Nielsen A
    Cell Transplant; 2018 Sep; 27(9):1407-1412. PubMed ID: 30056762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program.
    Kanda Y; Inoue M; Uchida N; Onishi Y; Kamata R; Kotaki M; Kobayashi R; Tanaka J; Fukuda T; Fujii N; Miyamura K; Mori SI; Mori Y; Morishima Y; Yabe H; Kodera Y
    Transplant Cell Ther; 2021 Aug; 27(8):664.e1-664.e6. PubMed ID: 33964514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease.
    Wagner JE; Rosenthal J; Sweetman R; Shu XO; Davies SM; Ramsay NK; McGlave PB; Sender L; Cairo MS
    Blood; 1996 Aug; 88(3):795-802. PubMed ID: 8704232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
    Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
    Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow of multiorgan donors underutilized: implications for improvement of accessibility of hematopoietic cells for transplantations.
    Baumert B; Kawa MP; Kotowski M; Grymuła K; Safranow K; Pabisiak K; Pius E; Peregud-Pogorzelski J; Walczak M; Ostrowski M; Machaliński B
    Transplantation; 2012 Jan; 93(2):165-71. PubMed ID: 22158516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease of L-selectin expression on human CD34+ cells on freeze-thawing and rapid recovery with short-term incubation.
    Hattori Y; Kato H; Nitta M; Takamoto S
    Exp Hematol; 2001 Jan; 29(1):114-22. PubMed ID: 11164112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
    Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
    Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manufacture of Autologous CD34
    Keever-Taylor CA; Heimfeld S; Steinmiller KC; Nash RA; Sullivan KM; Czarniecki CW; Granderson TC; Goldstein JS; Griffith LM
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1463-1472. PubMed ID: 28602891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice.
    Chen BP; Galy A; Kyoizumi S; Namikawa R; Scarborough J; Webb S; Ford B; Cen DZ; Chen SC
    Blood; 1994 Oct; 84(8):2497-505. PubMed ID: 7522631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34+ Stem Cell Selection and CD3+ T Cell Add-Back from Matched Unrelated Adult Donors in Children with Primary Immunodeficiencies and Hematological Diseases.
    Porta F; Comini M; Soncini E; Carracchia G; Maffeis M; Pintabona V; Bolda F; Beghin A; Schumacher RF; Lanfranchi A
    Transplant Cell Ther; 2021 May; 27(5):426.e1-426.e9. PubMed ID: 33965183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining post-thaw CD34+ cell dose of cryopreserved haematopoietic progenitor cells demonstrates high recovery and confirms their integrity.
    Reich-Slotky R; Colovai AI; Semidei-Pomales M; Patel N; Cairo M; Jhang J; Schwartz J
    Vox Sang; 2008 May; 94(4):351-7. PubMed ID: 18179677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of extended transport on cryopreserved allogeneic hematopoietic progenitor cell (HPC) product quality and optimal methods to assess HPC stability.
    Reddy OL; Sall MT; Dinh A; Cai Y; Ongkeko M; Arya N; Wilder J; Tran M; Jin P; Stroncek DF; Panch SR
    Transfusion; 2023 Apr; 63(4):774-781. PubMed ID: 36975826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.